JPMorgan Chase & Co. Purchases 105,824 Shares of Royalty Pharma plc (NASDAQ:RPRX)

JPMorgan Chase & Co. lifted its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 8.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,395,242 shares of the biopharmaceutical company's stock after purchasing an additional 105,824 shares during the quarter. JPMorgan Chase & Co. owned 0.24% of Royalty Pharma worth $35,593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of RPRX. Elo Mutual Pension Insurance Co lifted its stake in Royalty Pharma by 32.5% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 45,225 shares of the biopharmaceutical company's stock valued at $1,154,000 after acquiring an additional 11,089 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Royalty Pharma by 0.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 256,189 shares of the biopharmaceutical company's stock worth $6,620,000 after purchasing an additional 835 shares during the last quarter. Korea Investment CORP grew its position in Royalty Pharma by 43.8% in the 4th quarter. Korea Investment CORP now owns 224,272 shares of the biopharmaceutical company's stock worth $5,721,000 after purchasing an additional 68,300 shares during the period. Fox Run Management L.L.C. raised its stake in Royalty Pharma by 41.3% during the 4th quarter. Fox Run Management L.L.C. now owns 55,062 shares of the biopharmaceutical company's stock valued at $1,405,000 after buying an additional 16,084 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Royalty Pharma during the 4th quarter valued at $3,145,000. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Price Performance

Shares of RPRX traded up $0.74 during midday trading on Friday, hitting $31.95. 5,897,307 shares of the company traded hands, compared to its average volume of 3,242,342. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The firm has a 50 day moving average of $32.50 and a 200-day moving average of $29.14. The stock has a market cap of $18.42 billion, a price-to-earnings ratio of 22.03, a PEG ratio of 2.31 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.